144 ·Filed Jun 17, 2026

QURE

uniQure N.V.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001973379-26-000245
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The 10b5-1 plan mitigates opportunistic selling concern, but the accumulation of director sales in a short window warrants monitoring. Watch for the actual execution of this notice and any subsequent Form 4 filings. The pre-planned nature suggests no fundamental alarm, but if the stock weakens, this overhang could be a minor headwind.

DirectionNeutral
Confidencemedium
Horizondays
Latest settled — T+20d ⚠ clustered
QURE ▼ -14.97% at T+20d
NEUTRAL call ✗ call lost -14.97% · α vs SPY -15.50% · entry $46.29 → $39.36
Next anchor: T+60d due 18d ago
Latest observation: T+57 -35.72% FF3 residual α
Entry anchored
Jun 17, 04:02 PM ET
via exchange tick
T+1d
-4.10%
call -4.10% · α -3.79%
$44.39
settled 4mo ago
T+5d
+6.07%
call +6.07% · α +7.74%
$49.10
settled 3mo ago
T+20d
-14.97%
call -14.97% · α -15.50%
$39.36
settled 3mo ago
T+60d
—
call — · α —
—
due 18d ago

Price Chart

Loading chart...

Executive Summary

Director Madhavan filed Form 144 to sell 11,685 ordinary shares (~$526K) under a 10b5-1 plan adopted March 16, 2026. This follows two recent sales of 1,993 shares on June 11 and 10,000 shares on June 15, totaling ~$332K. While the advance notice signals intent, the pre-planned nature of the trades limits the bearish signal.

Key Facts

  • Director Balachandran Madhavan filed Form 144 to sell 11,685 ordinary shares.
  • Approximate market value of proposed sale: $526,462.64.
  • Sale is pursuant to a 10b5-1 plan adopted on March 16, 2026.
  • Madhavan also sold 1,993 shares on June 11, 2026 ($53,938.39) and 10,000 shares on June 15, 2026 ($278,530.84).
  • Total insider selling (filed + recent) in the past week: ~$858,931.87.

Financial Impact

Proposed sale of $526K plus recent sales of $332K total ~$859K, representing ~0.05% of $1.7B market cap.

Risk Factors

  • Insider selling overhang, though mitigated by 10b5-1 plan.
  • Further unplanned insider sales could signal deteriorating confidence.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001973379-26-000245
Document: 0001973379-26-000245-index.html0001973379-26-000245
Document: 0001973379-26-000245.txt0001973379-26-000245
32 reports for QURE
Performance horizon
67% Hit rate 6 of 9 directional calls best @ T+20▲ +27.15%Jul 29, 2026
Filters
Rows
Reports for QURE — sortable, filterable
TypeNow
Sep 2, 2026
4w ago
8-K
BULLISH ★ 7/10
$46.23 $44.47▼ −3.81%▼ −2.85%$23.46 (−49.25%)
Jul 29, 2026
9w ago
8-K
BULLISH ★ 8/10
$40.07 $44.24▲ +10.41%▲ +4.88%$23.46 (−41.45%)
Jul 7, 2026
12w ago
Insider Cluster
BEARISH ★ 5/10
$41.41 $41.52▼ −0.27%▲ +0.29%$23.46 (+43.35%)
Jul 2, 2026
13w ago
Insider Cluster
BEARISH ★ 4/10
$41.81 $44.48▼ −6.39%▼ −5.46%$23.46 (+43.89%)
Jul 2, 2026
13w ago
Insider Cluster
MIXED ★ 5/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jul 2, 2026
13w ago
144
NEUTRAL ★ 2/10
$41.81 $44.48▲ +6.39%▲ +5.46%$23.46 (−43.89%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 2/10
$45.17 $41.41▼ −8.32%▼ −8.59%$23.46 (−48.06%)
Jun 25, 2026
14w ago
144
BEARISH ★ 5/10
$47.51 $41.81▲ +12.00%▲ +14.16%$23.46 (+50.62%)
Jun 24, 2026
14w ago
424B5
MIXED ★ 6/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Jun 24, 2026
14w ago
144
NEUTRAL ★ 2/10
$49.10 $45.17▼ −8.00%▼ −9.56%$23.46 (−52.22%)
Showing 10 of 32

US Market Status

Market Closed — Opens Mon (64h 21m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access